Efficacy of SGLT2 Inhibitors in Adults With Sepsis

Launched by HOSPITAL AUTHORITY, HONG KONG · Jun 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effect of a type of medication called SGLT2 inhibitors on adults who are experiencing sepsis, a serious condition caused by an infection that can lead to organ failure. The main goal is to see if these medications can improve health outcomes for patients with sepsis, including any changes in inflammation in the body. Researchers want to find out if SGLT2 inhibitors are safe and effective for people in this critical state.

To participate in the trial, individuals must be at least 18 years old and have been diagnosed with sepsis within the last 48 hours. Participants should be able to take medications by mouth and provide consent for their involvement. However, those who have recently used SGLT2 inhibitors, have certain health conditions like unstable blood pressure or kidney issues, or are pregnant cannot join. If eligible, participants can expect to take the medication and be monitored closely by healthcare professionals throughout the study. This trial is currently recruiting participants, and your involvement could help advance understanding and treatment of sepsis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 years or above
• • New onset of sepsis within 48 hours defined according to the Sepsis-3 criteria. (≥2 SOFA)
• • Provision of signed and dated informed consent form from participant or surrogate
• • Ability to take and adhere to oral and enteral medication regimen
• • Willingness to comply
• Exclusion Criteria:
• • Current or recent use of SGLT2 inhibitors (within 12wks prior to randomization)
• • Impaired renal function
• • Clinically unstable or in refractory hypotension
• • History of ketoacidosis
• • Gastrointestinal surgery or GI absorption / malabsorption disorder
• • Pregnancy
• • Known allergic or hypersensitivity reactions to any SGLT2 inhibitors
• • Treatment with another investigational drug or other interventions within 30 days prior to trial